Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 48Calcium Dobesilate 20Bortezomib 20Lenalidomide 19Melphalan 16daratumumab 11Cyclophosphamide 11pomalidomide 10elotuzumab 8carfilzomib 8dexamethasone acetate 7pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5selinexor 5fludarabine 5auricularum 5Filgrastim 5liposomal doxorubicin 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Whole-Body Irradiation 3Vorinostat 3Simvastatin 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Adjuvants, Immunologic × Plasma cell × Clear all
NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡